Literature DB >> 17692648

Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation.

E Gringeri1, A Vitale, A Brolese, G Zanus, P Boccagni, D Neri, M Valmasoni, F D'Amico, F A Ciarleglio, A Carraro, A Pauletto, P Violi, D Bassi, F D'Amico, D F D'Amico, U Cillo.   

Abstract

INTRODUCTION: Liver transplantation represents the gold standard for the treatment of chronic liver disease. The whole transplantation process was assessed using an intention-to-treat analysis and considering patients from the time of their inclusion on the list and throughout lengthy follow-up.
MATERIALS AND METHODS: From January 1, 1999 to June 1, 2004, 373 adults joined the waiting list for liver transplantation at our institution. The main variables analyzed were: age, gender, etiology, Model for End-stage Liver Disease score, Child-Pugh class, United Network for Organ Sharing (UNOS) status. Global survival was evaluated using intention-to-treat analysis from the time of patient inclusion in the list to the end of their late follow-up.
RESULTS: The median waiting time was 20 months (range 0.1 to 70.2). By univariate analysis, the variables significantly influencing survival when patients joined the waiting list were: encephalopathy; ascites, poor nutritional status, Child-Pugh class C, UNOS 2, hepatitis C virus (HCV) and bilirubin > 2 mg/dL. By multivariate analysis, only HCV-related cirrhosis emerged as having an independent prognostic value. By intention-to-treat analysis, the 5-year survival rate was 67% and 79% for HCV-positive and HCV-negative patients, respectively (P = .0003).
CONCLUSIONS: HCV-related cirrhosis is an independent prognostic factor for survival according to an intention-to-treat analysis. Different inclusion criteria or treatments while on the waiting list and after transplantation need to be considered in the future for HCV-positive patients.

Entities:  

Mesh:

Year:  2007        PMID: 17692648     DOI: 10.1016/j.transproceed.2007.05.025

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

Review 1.  Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.

Authors:  Fabien Zoulim; T Jake Liang; Alexander L Gerbes; Alessio Aghemo; Sylvie Deuffic-Burban; Geoffrey Dusheiko; Michael W Fried; Stanislas Pol; Jürgen Kurt Rockstroh; Norah A Terrault; Stefan Wiktor
Journal:  Gut       Date:  2015-11       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.